- Market Capitalization, $K 552,975
- Shares Outstanding, K 118,410
- Annual Sales, $ 164,520 K
- Annual Income, $ -369,210 K
- 60-Month Beta 1.73
- Price/Sales 3.32
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+0.09 (+1.97%)since 08/24/21
| || |
-1.62 (-25.76%)since 06/24/21
| || |
-1.03 (-18.00%)since 09/24/20
Palm Beach, FL - September 20, 2021 – FinancialNewsMedia.com News Commentary – Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements...
PALM BEACH, Fla., /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective,...
--Initial data from LuMIERE study of targeted radiotherapy candidate FAP-2286 also expected in 2022
Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029"which delivers detailed overview of the global non-metastatic castration resistant prostate cancer treatment...
Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029" which delivers detailed overview of the hearing assistive technology (HAT) market in terms of market segmentation...
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in Switzerland. The Swiss authority responsible for the authorization and supervision of therapeutic...
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission ("SEC") to renew its previously established ATM facility under...
Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.
Clovis (CLVS) delivered earnings and revenue surprises of -7.02% and -9.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Wednesday reported a loss of $66.4 million in its second quarter.